CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
Status:
Completed
Trial end date:
2013-04-02
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine if therapy with the aldosterone antagonist, Eplerenone,
is associated with improved remodeling of the left ventricle in patients with cardiomyopathy.
We will determine if any benefit to cardiac remodeling is associated with improved clinical
outcomes, including improved exercise capacity and reduced incidence of major adverse cardiac
events such as death, hospitalization for heart-failure, serious heart rhythm disturbances
and transplantation.
The null hypothesis is that therapy with Eplerenone over 12 months is associated with an
improvement in cardiopulmonary exercise capacity and furthermore that treatment is associated
with improved clinical outcomes.
In order to test this hypothesis we will study stable patients on optimal drug therapy with
documented cardiomyopathy using a trial design where therapy will be randomized,
double-blinded and placebo-controlled. This will reduce the likelihood of any 'researcher
bias'. Patients will be recruited from the Heart-failure Service at the Royal Brompton
Hospital.